Tech Company Financing Transactions
Ovid Therapeutics Funding Round
On 8/12/2015, Ovid Therapeutics secured $75 million in Series B financing from Fidelity Management & Research Company and private investors.
Transaction Overview
Company Name
Announced On
8/12/2015
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
Fidelity Management & Research Company (Lead Investor)
Proceeds Purpose
Ovid plans to use the funds to advance several other internal compounds into clinical testing, and to further expand its pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1460 Bdwy.
New York, NY 10036
USA
New York, NY 10036
USA
Phone
Website
Email Address
Overview
Ovid Therapeutics Inc. (NASDAQ: OVID) is named for the Roman poet, Publius Ovidius Naso (Ovid), known for his epic work, Metamorphoses or Books of Transformations. Ovid is passionately committed to transforming the lives of patients with rare and orphan diseases of the brain--patients who currently have few if any treatment options or prospects for cure or improvement.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeremy Levin
Chief Medical Officer
Amit Rakhit
Controller
Timothy Daly
VP - Human Resources
Suzanne Wakamoto
VP - Regulatory Affairs
Claude Nicaise
Browse more venture capital transactions:
Prev: 8/12/2015: OptMed venture capital transaction
Next: 8/12/2015: Mogl venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs